ASND

Ascendis Pharma A/S [ASND] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

ASND Stock Summary

Top 10 Correlated ETFs

ASND

Top 10 Correlated Stocks

ASND

In the News

ASND Financial details

Company Rating
-
Market Cap
8.27B
Income
-481.45M
Revenue
266.72M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
879
Optionable
No
Shortable
Yes
Earnings
25 Apr 2024
P/E
-11.7
Forward P/E
-
PEG
6.58
P/S
43.73
P/B
-95.95
P/C
-
P/FCF
-11.6
Quick Ratio
2.38
Current Ratio
3.44
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-8.55
EPS next Y
-
EPS next Q
-
EPS this Y
-17.79%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
12.76%
Revenue last 5Y
81.95%
Revenue Q/Q
186.68%
EPS Q/Q
-46.88%
-
-
-
-
SMA20
2.53%
SMA50
4.64%
SMA100
17.34%
Inst Own
-
Inst Trans
-
ROA
-69%
ROE
-571%
ROC
-0.86%
Gross Margin
80%
Oper. Margin
-373%
Profit Margin
-396%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
66.03-161.0
52W High
+26.54%
52W Low
+208.68%
RSI
52
Rel Volume
0.46
Avg Volume
382.82K
Volume
177.99K
Perf Week
0.51%
Perf Month
3.06%
Perf Quarter
31.92%
Perf Half Y
23.56%
-
-
-
-
Beta
0.51
-
-
Volatility
1.81%, 6.32%
Prev Close
-0.96%
Price
203.73
Change
-0.61%

Something similar

Top by Market Cap
META
M&M.NS
NVDA
BRK-B
LLY
Top Correlated ETFs
DXSE.DE
ESIH.DE
LHTC.DE
SPYH.DE
EXV4.DE
Top Correlated Stocks
LLY
AZN
AVCT.L
ROG.SW
NGLD
Similar Market Cap
EFG
600201.SS
002583.SZ
0856.HK
603203.SS

Company Profile

Healthcare Biotechnology
  • Volume Average 382.82K
  • Market Capitalization 8.27B
  • Employee 879
  • CEO Mr. Jan Moller Mikkelsen
  • Headquarters Hellerup,DK
  • IPO Date 2015-01-28
  • Website https://ascendispharma.com

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.